New study aims to uncover hidden TB drug resistance

NCT ID NCT07169149

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study will test 250 people with tuberculosis (TB) to see how common drug resistance is. Using special rapid tests called GeneXpert, researchers will look for resistance to key TB drugs like Rifampicin. They also want to find out if things like diabetes or drug addiction make resistance more likely. The goal is to help doctors pick the right treatment faster.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could help doctors choose the most effective TB drugs for each patient, reducing treatment failure.

What could go wrong

This is an observational study, not a treatment trial. It will not directly benefit participants and may not lead to immediate changes in care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY AND EXTRA- PULMONARY TUBERCULOSIS (TB) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

extrapulmonary tuberculosis pulmonary tuberculosis tuberculosis Tuberculosis, Extrapulmonary

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Sohag University

    Sohag, Egypt

    Contact Phone: •••-•••-•••• Email: •••••@•••••